Testosterone Therapy for Men Over 50: What's Changing

If your interest in sex has vanished completely, as if a switch had been flipped, you might expect your doctor to shrug or hand you a pamphlet about aging gracefully. Many men in that position have low testosterone but no tumor, no injury and no genetic condition their doctors can point to. Under the old rulebook, that meant testosterone replacement therapy for these men over 50 was largely off the table as a labeled treatment. That rulebook is being rewritten.

What the FDA Said and Why It Matters

On April 16, 2026, the FDA made an announcement that drew close attention in men's health circles. The agency signaled it is encouraging manufacturers of approved testosterone products to submit supplemental applications for a potential new indication: treating low libido in men with idiopathic hypogonadism. That term needs some unpacking.

Idiopathic hypogonadism means your testosterone is clinically low (typically under 300 ng/dL) but doctors can't find a specific structural or genetic reason why: no pituitary tumor, no Klinefelter syndrome, no radiation damage. For years, that "no known cause" distinction kept many men in a gray zone. The existing FDA label for testosterone therapy only covered hypogonadism tied to a documented underlying condition. If your labs were low but unexplained, you were navigating off-label territory, which created confusion for both patients and prescribers.

The FDA's April 16 press announcement didn't approve anything, at least not yet. Think of it as the agency raising its hand and saying: we've seen enough credible evidence to invite a formal conversation. Manufacturers have until April 30, 2026 to contact the FDA about submitting supplemental NDAs. Any actual approval would still require rigorous clinical evidence and a full risk-benefit review. Still, the direction of travel is clear, and it matters.

The Science That Moved the Needle

The FDA doesn't send signals like this into a vacuum. Behind this announcement is a body of research that's been building for years, culminating in a December 2025 expert panel meeting that apparently gave regulators enough confidence to act.

The study that keeps coming up in this conversation is the TRAVERSE Sexual Function Study, a large randomized controlled trial that enrolled 1,161 men between the ages of 45 and 80. All of them had testosterone levels under 300 ng/dL and reported low libido. Over two years, researchers tracked what happened when these men received testosterone therapy versus a placebo. What surprised researchers, or at least confirmed what many clinicians had suspected, was how consistent the results were. According to the TRAVERSE Sexual Function Study published in the Journal of Clinical Endocrinology & Metabolism, TRT significantly improved sexual activity, hypogonadal symptoms, and sexual desire compared to placebo across the two-year period. The FDA cited this trial directly in its April 2026 preliminary assessment.

The trial covered over a thousand middle-aged and older men in a controlled setting, and they showed meaningful, measurable improvement. The Federal Register notice published four days later, on April 20, 2026, reinforced the point: the formal Federal Register notice stated that the FDA's preliminary review of prospective, controlled clinical trials found TRT "may be safe and effective" for this population.

Why "Idiopathic" Has Always Been the Sticking Point

Idiopathic hypogonadism is the most common form. Many men walking around with chronically low testosterone don't have a diagnosable underlying cause. Age-related testosterone decline, metabolic changes, sleep disruption, and chronic stress all play roles that are difficult to pin to a single culprit. So the irony has always been that the men most likely to show up in a doctor's office with this problem were also the ones least likely to qualify for a labeled treatment.

Low libido in this context reaches beyond the bedroom. It often comes bundled with fatigue, mood shifts, reduced motivation, and a general sense of flatness that men over 50 are too frequently told to accept. When testosterone levels sit chronically below 300 ng/dL, the body notices, even when the cause is unknown. Clinicians have known this for a long time. What's been missing is the regulatory framework to act on it cleanly.

That is what makes the FDA's move meaningful. It goes beyond a policy tweak and acknowledges that "we don't know why" shouldn't automatically translate to "we won't treat it."

What This Means If You're a Man Over 50 With Low Libido

Before you schedule an appointment expecting a new prescription, be clear on one point: nothing has been approved yet. The FDA's announcement is an invitation to manufacturers, not a green light for patients. A label change, if it comes, would follow supplemental NDA submissions, FDA review, and a formal approval process that takes months at minimum, potentially longer.

That said, this is the moment to get informed and start an honest conversation with your doctor. If you've noticed a significant drop in libido, get your testosterone levels checked. A blood test done in the morning, when levels are highest, gives the most accurate picture. Many men are surprised to find their levels below the clinical threshold of 300 ng/dL, so knowing your number matters.

Testosterone therapy is also not a one-size solution. TRT carries real considerations, including effects on red blood cell production, cardiovascular factors, fertility, and prostate health, all of which your doctor will want to weigh based on your individual history. The FDA's review process exists to ensure that when an expanded indication does arrive, the risk-benefit math has been done carefully. Being an informed patient means walking into that conversation knowing your labs, your symptoms, and your questions.

If your doctor's notes or lab results feel small on the screen, the Magnifier tool in SteadiDay Premium can help you read them clearly on your phone, which helps when you're trying to stay on top of your health details.

Video: Mayo Clinic Minute - How low testosterone can affect men's health -- Mayo Clinic

Keeping Perspective: Testosterone Therapy Is Not a Magic Reset

With news like this, it's easy to imagine testosterone therapy as a fountain of youth in a syringe, which it isn't. The TRAVERSE data showed meaningful improvements in sexual desire and activity, but "meaningful" in clinical trial language means statistically significant compared to placebo. Individual results vary, onset takes weeks to months, and the therapy requires ongoing monitoring.

Sleep quality, exercise, stress levels, and cardiovascular health all interact with testosterone in ways that matter. Men who come to TRT while also addressing sleep apnea (which independently suppresses testosterone) or who pair it with consistent resistance training tend to see better outcomes than those treating it as a standalone fix. Think of any hormonal therapy as one part of a larger picture, not the whole frame.

The research community is watching this regulatory moment closely. As Urology Times and AJMC have noted in their coverage of the April 2026 announcement, this potential label expansion could meaningfully change how primary care physicians and urologists approach low libido in men with unexplained low testosterone, reducing the hesitation that has historically surrounded off-label prescribing in this space.

What to Do Right Now

You don't need to wait for FDA approval to take the first useful step. If you're a man over 50 whose libido has dropped in a sustained, noticeable way, beyond the ordinary ebb of a busy week, bring it up at your next appointment. Ask for a morning testosterone panel. If your level comes back below 300 ng/dL without a clear structural cause, you're the population this regulatory discussion is about.

Write down your symptoms before you go. How long has this been happening? Has your energy or mood shifted too? Are you sleeping well? These details help your doctor build a fuller picture and make the conversation more productive than a two-minute check-in allows.

If your levels do come back low, your doctor can keep an eye on the FDA process while the two of you work on sleep and exercise, laying the groundwork for whatever the next chapter of treatment looks like. Staying informed, staying in the conversation, and not dismissing your own symptoms as inevitable is where it starts.

The science is moving and regulators are listening. For men over 50 with questions about testosterone replacement therapy, this moment is worth paying attention to.